Factors Contributing to Platelet Hyperactivity in Diabetes Mellitus

  • E. Dupuy
  • P. J. Guillausseau
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)


Diabetes mellitus is associated with a high prevalence of atherosclerotic and microvascular disease (31). Platelets may play a part in the development of these vascular complications. Hyperag-gregability is frequently reported in diabetes mellitus (1, 2, 7–9, 11, 16, 20, 27). Some factors which could contribute to platelet hyperactivity have been studied.


Platelet Aggregation Diabetic Subject Platelet Factor Proliferative Retinopathy Increase Platelet Aggregation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. Bensoussan, S. Levy-Toledano, P. Passa, J. Caen, J. Canivet, Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologia 11:307–312 (1975).PubMedCrossRefGoogle Scholar
  2. 2.
    D. Bensoussan, S. Levy-Toladano, P. Passa, Anomalies de l’hémostase primaire au cours de la microangiopathie diabétique. Nouv. Pres. Med. 36:2383–2386 (1976).Google Scholar
  3. 3.
    G. Born, M. Cross, Effects of inorganic ions and plasma proteins on the aggregation of blood platelets by adenosine diphosphate. J. Physiol. (London) 170:397–414 (1964).PubMedGoogle Scholar
  4. 4.
    D. Borsey, J. Dawes, D. Fraser, C. Prowse, R. Elton, B. Clarke, Plasma β-thromboglobulin in diabetes mellitus. Diabetologia 18:353–357 (1980).PubMedGoogle Scholar
  5. 5.
    A. Burrows, S. Chavin, T. Hockaday, Plasma β-thromboglobulin concentrations in diabetes mellitus. Lancet 1:253–237 (1978).Google Scholar
  6. 6.
    J. Campbell, J. Dawes, D. Fraser, D. Pepper, B. Clarke, L. Duncan, J. Cash, Plasma β-thromboglobulin in diabetes mellitus. Diabetes 26:1175–1177 (1977).PubMedCrossRefGoogle Scholar
  7. 7.
    B. Coller, R. Frank, R. Milton, H. Gralnick, Plasma cofactors of platelet function: correlation with diabetic retinopathy and hemoglobins Ala-c. Ann. Intern. Med. 88:311–316 (1978).PubMedGoogle Scholar
  8. 8.
    J. Colwell, P. Halushka, Platelet function in diabetes mellitus. Brit. J. Haemat. 44:521–526 (1980).PubMedCrossRefGoogle Scholar
  9. 9.
    J. Davis, P. Phillips, K. Yve, H. Lewis, C. Hartman, Platelet aggregation. Adult onset diabetes mellitus and coronary artery disease. JAMA 239:732–734 (1980).CrossRefGoogle Scholar
  10. 10.
    M. Denham, M. Fischer, G. James, M. Hassan, β-thromboglobulin in clinical conditions. Lancet 1:1154–1158 (1977).Google Scholar
  11. 11.
    E. Dupuy, P. Guillausseau, P. Gaudel, G. Kartalis et al., Fonctions plaquettaires et angiopathie diabétique. Nouv. Pres. Med. 8:3123–3125 (1979).Google Scholar
  12. 12.
    J. Gerrard, M. Stuart, G. Rao, M. Steffes, M. Hauer, D. Brown, Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J. Lab. Clin. Med. 95:950–958 (1980).PubMedGoogle Scholar
  13. 13.
    P. Halushka, D. Lurie, J.A. Colwell, Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. N. Engl. J. Med. 297:1306–1310 (1977).PubMedCrossRefGoogle Scholar
  14. 14.
    P. Halushka, J.A. Colwell, C. Rogers, C. Loadholt, B. Garner, Increased thromboxane (TXB2) synthesis by platelets from patients with diabetes mellitus (DM): studies with a TX synthetase inhibitor and a TX receptor antagonist. Clin. Res. 27:269 A (1979).Google Scholar
  15. 15.
    M. Hamberg, J. Svensson, B. Samuelsson, Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. 72:2994–2998 (1975).PubMedCrossRefGoogle Scholar
  16. 16.
    H. Kwaan, J. Colwell, S. Cruz, N. Survenwela, J. Dobbie, Increased platelet aggregation in diabetes mellitus. J. Lab. Clin. Med. 80:236–246 (1972).PubMedGoogle Scholar
  17. 17.
    M. Lagarde, M. Dechavanne, Increase of platelet prostaglandin cycle endoperoxides in thrombosis. Lancet I:88 (1977).CrossRefGoogle Scholar
  18. 18.
    H. Lee, A. Nurden, A. Thomaidis, J. Caen, Relationship between fibrinogen binding and the platelet glycoprotein deficiencies in Glanzmann’s thrombasthenia type I and type II. Br. J. Haemat. in press.Google Scholar
  19. 19.
    H. Lee, C. Paton, P. Passa, J. Caen, Fibrinogen binding and ADP induced aggregation in platelets from diabetic subjects, (submitted for publication).Google Scholar
  20. 20.
    G. Leone, B. Bizzi, F. Accorra, P. Boni, Functional aspects of platelets in diabetes mellitus. In: Platelet aggregation and drugs. L. Caprino and F. Rossi eds., Academic Press New York, p.49–61 (1974).Google Scholar
  21. 21.
    S. Levy-Toledano, A. Demoszynska, E. Dupuy, P. Gaudel, J. Lubetzki, J. Caen, P. Castaldi, Platelet coagulant activities in diabetic patients. In: Cellular and biochemical aspects in diabetic retinopathy. INSERM symposium n° 7, 69–74 (1978).Google Scholar
  22. 22.
    C. Ludlam, J. Cash, Studies on the liberation of β-thromboglobulin from human platelets in vitro. Br. J. Haematol. 33: 239–249 (1976).PubMedCrossRefGoogle Scholar
  23. 23.
    G. Marguerie, T. Edgington, E. Plow, Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J. Biol. Chem. 255: 154–161 (1980).PubMedGoogle Scholar
  24. 24.
    S. Moncada, S. Grygelowski, S. Bunting, J. Vane, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–666 (1976).PubMedCrossRefGoogle Scholar
  25. 25.
    S. Moncada, E. Higgs, J. Vane, Human arterial and venous tissues generate prostacyclin, a potent inhibitor of platelet aggregation. Lancet 1:18–22 (1977).PubMedCrossRefGoogle Scholar
  26. 26.
    S. Moore, D. Pepper, D. Cash, The isolation and characterization of a platelet specific β-globulin (βthromboglobulin) and the detection of anti-urokinase and anti-plasmin released from thrombin-aggregated washed human platelets. Biochem. Biophys. Acta 379:360–369 (1975).PubMedCrossRefGoogle Scholar
  27. 27.
    J. Mustard, M. Packham, Platelets and diabetes mellitus. New Engl. J. Med. 297:1345–1347 (1977).PubMedCrossRefGoogle Scholar
  28. 28.
    E. Peerschke, M. Zucker, R. Grant, J. Egan, M. Johnson, Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 55:841–847 (1980).PubMedGoogle Scholar
  29. 29.
    F. Preston, J. Ward, B. Marcola, N. Porter, W. Timperley, B. O’Malley, Elevated β-thromboglobulin and circulating platelet aggregates in diabetic microangiopathy. Lancet I: 238–240 (1978).CrossRefGoogle Scholar
  30. 30.
    C. Redman, M. Allington, F. Bolton, G. Stirrat, Plasma β-thromboglobulin in pre-eclampsia. Lancet 2:248–251 (1977).PubMedCrossRefGoogle Scholar
  31. 31.
    H. Root, E. Bland, W. Gordon, Coronary atherosclerosis in diabetes mellitus. A post-mortem study. JAMA 113:27–30 (1939).CrossRefGoogle Scholar
  32. 32.
    J. Sagel, J. Colwell, L. Crook, M. Laimins, Increased platelet aggregation in early diabetes mellitus. Ann Intern. Med. 82: 733–738 (1975).PubMedGoogle Scholar
  33. 33.
    K. Sarji, H. Schraibman, A. Chambers, R. Nair, J. Colwell, Quantitative studies on von Willebrand factor in normal and diabetic subjects, role of vWF in second-phase platelet aggregation. Microcirculation 2:296–297 (1976).CrossRefGoogle Scholar
  34. 34.
    P. Walsh, The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Brit. J. Haematol. 22: 393–405 (1972).CrossRefGoogle Scholar
  35. 35.
    P. Walsh, Platelet coagulant activities and haemostasis. A hypothesis. Blood 43:597–605 (1974).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • E. Dupuy
    • 1
  • P. J. Guillausseau
    • 1
  1. 1.Département d’Hematologie BiologiqueHôpital LariboisiereParisFrance

Personalised recommendations